Biotech Stocks Soar Amid Positive News

A number of biotech stocks were soaring in Friday's premarket following positive news.

Biogen Idec Inc BIIB announced data from a pre-specified interim analysis of PRIME, the Phase 1b study of aducanumab (BIIB037) which showed statistical significance with 3mg, 10mg doses for Alzheimer's treatment.

Biogen Idec traded at $464.71 in the premarket, up 7.16 percent

Gilead Sciences, Inc. GILD moved higher following positive comments from Argus, which expected continued strength for its antiviral and oncology drugs.

Gilead Sciences traded at $102.40, up 0.95 percent.

Prothena Corporation PLC PRTA reported that its PRX002 protein Immunotherapy for Parkinson's Disease met primary objective of Phase 1 study, found to be safe, well tolerated.

Prothena soared to $41.87 in the premarket, up 43.24 percent.

Intercept Pharmaceuticals Inc ICPT reported that data showed OCA-treated patients with nonalcoholic steatohepatitis (NASH) saw improvements in its Phase 2b FLINT trial.

Intercept Pharmaceuticals surged 8 percent to $311.71.

Posted In: BiotechNewsMoversGeneral
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...